Wenwen Sun1, Xuwei Gui1, Zheyuan Wu2, Yangyi Zhang3, Liping Yan4. 1. Shanghai Clinical Research Center for Infectious Disease (Tuberculosis), Department of Tuberculosis and Shanghai Key Lab of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, No. 507 Zhengmin Road, Shanghai, 200433, China. 2. Tuberculosis Prevention Division, Shanghai Center for Disease Control and Prevention, Shanghai, China. 3. Tuberculosis Prevention Division, Shanghai Center for Disease Control and Prevention, Shanghai, China. zhangyangyi@scdc.sh.cn. 4. Shanghai Clinical Research Center for Infectious Disease (Tuberculosis), Department of Tuberculosis and Shanghai Key Lab of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, No. 507 Zhengmin Road, Shanghai, 200433, China. 13564641601@163.com.
Abstract
OBJECTIVES: Our aim was to assess the ability of the Whole-genome sequencing (WGS) in predicting drug resistance profile of multidrug-resistant mycobacterium tuberculosis (MDR-MTB) from newly diagnosed cases in China. METHODS: We validated the Phenotypic drug Sensitivity Test (pDST) for 12 anti-tuberculosis drugs using the Bactec MGIT 960 system. We described the characteristics of the isolates enrolled and compared the pDST results with resistance profiles predicted by WGS. RESULTS: The pDST showed that of the 43 isolates enrolled, 25.6% were sensitive to rifabutin (RFB); 97.7%、97.7%、93.0% and 93.0% were sensitive to cycloserine (Cs), amikacin/kanamycin (Ak/Km), para-aminosalicylic acid (Pas) and ethionamide Eto), respectively; 18.6% were resistant to fluoroquinolones (FQs) or second-line injections. Genotype DST determined by WGS of Ak/Km、Eto and RFP reached high consistency to 97.7% compared with pDST, followed by moxifloxacin (Mfx) 95.3%, levofloxaci (Lfx) and Pas 93%, streptomycin (Sm) 90.3%. The genotype DST of RFB and EMB showed low consistency with the pDST of 67.2 and 79.1%. WGS also detected 27.9% isolates of pyrazinamide(PZA)-related drug-resistant mutation. No mutations associated with linezolid (Lzd), bedaquiline (Bdq) and clofazimine (Cfz) were detectd. CONCLUSIONS: WGS has the potential to infer resistance profiles without time-consuming phenotypic methods, which could be provide a basis to formulate reasonable treatment in high TB burden areas.
OBJECTIVES: Our aim was to assess the ability of the Whole-genome sequencing (WGS) in predicting drug resistance profile of multidrug-resistant mycobacterium tuberculosis (MDR-MTB) from newly diagnosed cases in China. METHODS: We validated the Phenotypic drug Sensitivity Test (pDST) for 12 anti-tuberculosis drugs using the Bactec MGIT 960 system. We described the characteristics of the isolates enrolled and compared the pDST results with resistance profiles predicted by WGS. RESULTS: The pDST showed that of the 43 isolates enrolled, 25.6% were sensitive to rifabutin (RFB); 97.7%、97.7%、93.0% and 93.0% were sensitive to cycloserine (Cs), amikacin/kanamycin (Ak/Km), para-aminosalicylic acid (Pas) and ethionamide Eto), respectively; 18.6% were resistant to fluoroquinolones (FQs) or second-line injections. Genotype DST determined by WGS of Ak/Km、Eto and RFP reached high consistency to 97.7% compared with pDST, followed by moxifloxacin (Mfx) 95.3%, levofloxaci (Lfx) and Pas 93%, streptomycin (Sm) 90.3%. The genotype DST of RFB and EMB showed low consistency with the pDST of 67.2 and 79.1%. WGS also detected 27.9% isolates of pyrazinamide(PZA)-related drug-resistant mutation. No mutations associated with linezolid (Lzd), bedaquiline (Bdq) and clofazimine (Cfz) were detectd. CONCLUSIONS: WGS has the potential to infer resistance profiles without time-consuming phenotypic methods, which could be provide a basis to formulate reasonable treatment in high TB burden areas.
Authors: J Luna-Herrera; G Martínez-Cabrera; R Parra-Maldonado; J A Enciso-Moreno; J Torres-López; F Quesada-Pascual; R Delgadillo-Polanco; S G Franzblau Journal: Eur J Clin Microbiol Infect Dis Date: 2003-01-25 Impact factor: 3.267
Authors: Vanessa Mathys; René Wintjens; Philippe Lefevre; Julie Bertout; Amit Singhal; Mehdi Kiass; Natalia Kurepina; Xiao-Ming Wang; Barun Mathema; Alain Baulard; Barry N Kreiswirth; Pablo Bifani Journal: Antimicrob Agents Chemother Date: 2009-02-23 Impact factor: 5.191
Authors: Matthias Merker; Camille Blin; Stefano Mona; Nicolas Duforet-Frebourg; Sophie Lecher; Eve Willery; Michael G B Blum; Sabine Rüsch-Gerdes; Igor Mokrousov; Eman Aleksic; Caroline Allix-Béguec; Annick Antierens; Ewa Augustynowicz-Kopeć; Marie Ballif; Francesca Barletta; Hans Peter Beck; Clifton E Barry; Maryline Bonnet; Emanuele Borroni; Isolina Campos-Herrero; Daniela Cirillo; Helen Cox; Suzanne Crowe; Valeriu Crudu; Roland Diel; Francis Drobniewski; Maryse Fauville-Dufaux; Sébastien Gagneux; Solomon Ghebremichael; Madeleine Hanekom; Sven Hoffner; Wei-wei Jiao; Stobdan Kalon; Thomas A Kohl; Irina Kontsevaya; Troels Lillebæk; Shinji Maeda; Vladyslav Nikolayevskyy; Michael Rasmussen; Nalin Rastogi; Sofia Samper; Elisabeth Sanchez-Padilla; Branislava Savic; Isdore Chola Shamputa; Adong Shen; Li-Hwei Sng; Petras Stakenas; Kadri Toit; Francis Varaine; Dragana Vukovic; Céline Wahl; Robin Warren; Philip Supply; Stefan Niemann; Thierry Wirth Journal: Nat Genet Date: 2015-01-19 Impact factor: 38.330
Authors: Frederick A Sirgel; Robin M Warren; Erik C Böttger; Marisa Klopper; Thomas C Victor; Paul D van Helden Journal: PLoS One Date: 2013-03-19 Impact factor: 3.240
Authors: Otavio T Ranzani; Laura C Rodrigues; Sidney Bombarda; Cátia M Minto; Eliseu A Waldman; Carlos R R Carvalho Journal: Lancet Infect Dis Date: 2019-10-31 Impact factor: 71.421